A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the first time that a microRNA component of this region-miR-383-is frequently downregulated in prostate cancer, has a critical role in determining tumor-initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor-initiating cells (TICs)/stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggest that miR-383 regulates PCa tumor-initiating/stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor-initiating capacity of CD44+ PCa cells. Also, 'anti-metastatic' effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identified a novel finding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggest that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identified miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA.
INTRODUCTION
A critical challenge in prostate cancer (PCa) clinical management is posed by its high rates of recurrence and metastasis, often attributed to the existence of tumor-initiating cells (TIC) or PCa stem cells (CSC) within the bulk of tumor. 1, 2 CSCs have been identified in human prostate tumors and are associated with poor prognosis 1 as these cells are highly tumorigenic, often causing tumor relapse, metastases and therapy resistance. 3, 4 In human PCa, these cells are typically characterized by the expression of cell surface adhesion marker CD44 1, [5] [6] [7] [8] [9] and other markers. The predominant stem cell marker, CD44, is a transmembrane receptor for hyaluronan, that has critical roles in cellular adhesion, migration, signaling and tumor metastasis. 10 Tumor cells positive for this marker (CD44+) are more proliferative, clonogenic, tumorigenic and metastatic than the isogenic CD44 − cells. 7 Considering the challenges that CD44+ CSCs pose for effective PCa therapy, it is imperative to understand the molecular controls that regulate this subpopulation.
The prostate cancer genome is characterized by a frequent loss of chromosome 8p (chr8p) [11] [12] [13] [14] [15] [16] [17] with approximately 30-50% of cases presenting this genomic alteration. A common region of loss of heterozygosity (LOH) has been mapped to the chr8p22 locus 18, 19 within this region. Genomic studies implicate this region as the site for candidate tumor suppressor genes (TSGs), 20 such as lipoprotein lipase (LPL), although the TSGs within this region has not been fully characterized to date. Studies suggest that chr8p deletion is an important event in both the initiation and metastasis of PCa. 21 High frequency of LOH at chr8p22 is usually observed in high-grade prostate tumors suggesting the existence of a novel putative PCa tumor suppressor gene. 21 Considering the association of loss of this chromosomal region in PCa with poor prognosis, 22 it is crucial to define the role of genetic elements within this region. Thus, the focus of this study was to define the role of microRNA (miRNA) genes located in the frequently deleted chr8p22 region in prostate cancer. MicroRNA genes are often located in fragile chromosomal regions involved in cancers. 23 miRNAs are small non-coding RNA molecules (containing~22 nucleotides) that suppress gene expression post transcriptionally via sequence-specific interactions with the 3ʹ-untranslated regions (UTRs) of cognate mRNA targets. 24 In a preliminary screen, we identified that miR-383 is significantly downregulated in prostate cancer. miR-383 is located in the chr8p22 region within intron 3 of the sarcoglycan zeta (SGCZ) gene. 25 Downregulation of microRNA-383 has been associated with male infertility and has been reported to promote testicular embryonal carcinoma cell proliferation by targeting interferon regulatory factor-1 (IRF1). 26 miR-383 has also been reported to be downregulated in gliomas and medulloblastomas and inhibits cell proliferation, migration, invasion and induces apoptosis via targeting of cyclin D1, GADD45G (growth arrest and DNA-damage-inducible 45 gamma), peroxiredoxin 3 and insulin-ike growth factor receptor 1.
carcinomas by directly targeting ROBO3. 32 These studies point to an important regulatory role of miR-383. However, the role of miR-383 in prostate cancer has never been reported. Here we provide the first evidence that (i) miR-383 is dysregulated in prostate cancer; (ii) miR-383 is a microRNA component of frequently deleted chr8p22 locus that is a critical determinant of PCa TIC/stemness via regulation of CD44, a ubiquitous marker of PCa stem cells; (iii) miR-383 is a potential novel PCa diagnostic biomarker; (iv) miR-383 is an important 'anti-metastatic' microRNA in PCa. To our knowledge, this is the first study that associates a long studied frequently lost chromosomal region with PCa TICs via loss of a microRNA component of the region.
RESULTS
MicroRNA-383 located in frequently deleted chr8p22 region is under expressed in prostate cancer miR-383 is located in a common region of LOH at the chr8p22 locus 18, 19 within the host gene SGCZ (Figure 1a) . We analyzed copy-number alterations at this locus in prostate adenocarcinomas in The Cancer Genome Atlas (TCGA) dataset. 33, 34 miR-383 locus was deleted either homozygously or heterozygously iñ 48% PCa cases suggesting that prostate tumors are associated with genomic deletion of this miRNA (Figure 1b) . On the basis of this, we hypothesized that miR-383 expression is lost in PCa and may underlie PCa initiation, progression and metastasis. To test our hypothesis, we analyzed miR-383-5p (major form of miR-383, referred as miR-383) expression in a large cohort of PCa clinical specimens (Figures 1c and d) . miR-383 expression analyses in the TCGA cohort (training cohort) for a set of 187 primary prostate adenocarcinoma cases (Figure 1c ) suggest that~72% of PCa cases exhibit miR-383 downregulation. Next we performed miR-383 expression profiling in an independent trainingvalidation cohort of 112 patients seen at SFVAMC (Figure 1d ). miR-383 expression was analyzed in laser capture microdissected PCa tissues (n = 112) and matched adjacent normals by real-time PCR (Figure 1d ) and was found to be significantly downregulated in~76% of PCa cases (P = 0.0003). Nine percent of PCa cases showed no change and~15% of cases exhibited high miR-383 expression. Average miR-383 expression in tumor tissues was approximately fourfold lower than that of normal tissues (P = 0.0500; Figure 1e ). Patients' demographics and clinicopathological characteristics are summarized in Supplementary  Table S1 . We also analyzed copy-number alterations within a small subset of SFVAMC cohort (n = 22) and found that tumor tissues show a heterozygous or homozygous loss at miR-383 locus iñ 46% of tissues compared with adjacent normals (Figure 1f ). Also, we examined correlation between copy-number alterations at this locus and miR-383 expression within this subset (Figure 1g ) and found a positive correlation (correlation co-efficient = 0.563, P = 0.0042). Further, miR-383 expression analyses in prostate cell lines showed that its expression is specifically attenuated in PCa cell lines (LNCaP, DU145, PC3, LAPC9) compared with normal primary prostate epithelial cells (Figure 1h ). Collectively, these data confirm the widespread downregulated expression of miR-383 in PCa.
Low miR-383 expression is associated with poor survival outcome in prostate cancer In view of the observed widespread downregulation of miR-383 expression in PCa clinical specimens, we performed analyses to assess whether low miR-383 expression has associated prognostic potential. Kaplan-Meier survival analysis of prostate cancer patients (SFVAMC and TCGA cohort) was performed where patients were stratified into low/high miR-383 expression groups (Figure 2a ). Our analyses showed that patients with low miR-383 expression had significantly poor survival outcome (P = 0.0102) with the survival probability reduced to~81%. (Figure 2b ). Interestingly, we observed a significant inverse correlation between miR-383 and serum PSA levels (P = 0.0001). Patients with high serum PSA levels (PSA44) exhibited low miR-383 expression. Further, we stratified our clinical cohort based on age and PSA and used age-adjusted PSA ranges to examine the correlation between miR-383 expression and serum PSA (Supplementary Table S3 ). We found that miR-383 expression was statistically correlated with age-adjusted PSA levels (P = 0.0007). Low miR-383 expression was observed in 54% of cases with normal age-adjusted PSA levels and in 81% of cases with high PSA levels. Although there was no significant correlation with age and Gleason score, decreased miR-383 expression was observed in 76% of cases of pathological stage pT2, 79% of cases of pT3 and 100% of pT4 cases (Figure 2b) . Similarly, in the TCGA cohort, low miR-383 expression was observed in 65% of pT2, 74% of pT3 and 100% of pT4 cases. Also, low miR-383 expression was observed in 80% and 75% of cases with biochemical recurrence within the SFVAMC and TCGA cohorts, respectively. However, the correlations between miR-383 expression and pathological stage and biochemical recurrence failed to achieve statistical significance (Figure 2b ). miR-383 is a potential novel diagnostic biomarker for prostate cancer In view of the observed correlation between miR-383 expression and serum PSA, we evaluated the diagnostic potential of miR-383 ( Figure 3 ). Receiver Operating Characteristic (ROC) curve analyses showed that miR-383 expression can be a single significant parameter to discriminate between normal and tumor tissues with an area under the ROC curve (AUC) of 0.94 (95% CI: 0.90-0.98, P = 1.696997e − 21; Figure 3a) . The discriminatory ability of miRNA was further characterized using apparent prevalence, true prevalence, sensitivity, specificity, positive predictive value, negative predictive value and positive likelihood ratio (Figure 3b ). These analyses showed that miR-383 as PCa diagnostic biomarker exhibits 100% sensitivity, 72% specificity, 78% positive predictive value and 100% negative predictive value. We also compared the diagnostic ability of miR-383 expression with that of serum PSA, the most widely used PCa biomarker. miR-383 expression outperformed PSA as a diagnostic biomarker in our patient cohort, with PSA showing an AUC of 0.80 (95% CI: 0.71-0.88; Figure 3c ). The difference between diagnostic abilities of miR-383 vs serum PSA were statistically significant (P = 0.003). Further, a logistic regression model was employed to compare the ability of miRNA and PSA to identify a tumor sample by comparing probability of tumor conditional on miRNA values vs that of PSA values ( Figure 3d ). Our analyses suggest that miR-383 is a better diagnostic classifier. As PSA changes (along the x axis) increasing the probability of tumor, the separation between tumor and normal samples is not apparent (Figure 3d ). On the other hand, when miR-383 expression changes (along the y axis) increasing the probability of tumor, the majority of These data suggest that endogenous miR-383 expression is vital to maintain prostate cells in normal untransformed state and miR-383 loss initiates tumorigenicity in these cells.
miR-383 directly regulates prostate cancer stem cell marker CD44 Ongoing studies in our laboratory on microRNA genes located in the frequently deleted chr8p region suggest that these genes are (e) ROC curve analysis for combined potential of miR-383 and PSA to distinguish between malignant and normal tissues (*P o0.05).
miR-383 regulates CD44 N Bucay et al important players in PCa epithelial to mesenchymal transition (EMT), stemness and PCa progression and metastasis (unpublished data). In silico analyses using miRANDA 35 algorithm identified that miR-383 potentially targets an array of stemness-related genes including CD44, LIN28A, STAT3 and LEF1 (Supplementary Table S4 ). We performed western blot analyses to validate these targets after miR-383 overexpression (Supplementary Figure S3) . Our analyses showed that only CD44 levels were subject to regulatory control by miR-383. Quantitative real-time PCR (qRT-PCR) and immunoblotting analyses of mock/miR-CON/miR-383 overexpressing DU145/PC3/LNCaP cells confirmed that miR-383 expression represses CD44 mRNA and protein expression (Figures 5a and b;  Supplementary Figure S4 ). This repression was confirmed in bioluminescent PC-3M-luc-C6 cells stably transfected with control miR/miR-383 (Figures 5a and b) . To verify that these effects on CD44 expression are as a result of direct interaction of miR-383 with the corresponding microRNA response element (MRE)/ binding site within CD44 3′-UTR (Figure 5c ), we performed luciferase reporter assays with CD44 3′UTR/Control 3′UTR in miR-CON/miR-383 transfected DU145/PC3 cells (Figure 5d) . A significant decrease in CD44 3′-UTR luciferase activity was observed upon miR-383 transfection in both cell lines confirming CD44 as a direct miR-383 target. To validate CD44 as direct miR-383 target, we mutated the putative miR-383 binding site in CD44 3′-UTR (represented in Figure 5c ). Transfection of mutant CD44 3′UTR/ control 3′UTR in miR-CON/miR-383 transfected DU145/PC3 cells showed that mutation of the miR-383-binding site prevented the repression of luciferase activity observed upon miR-383 overexpression in DU145 and PC3 cells (Figure 5d ). Since CD44 is a predominant cell surface marker of PCa TICs, 1,5-9 we next examined the regulation of TICs by miR-383. We purified CD44+ and CD44 − cell populations from PCa xenografts generated from DU145, PC3 and LAPC9 cell lines (Supplementary Figure S5) and profiled miR-383 expression (Figure 5e ). The average percentage CD44 is a functionally relevant target of miR-383 in prostate cancer To determine whether CD44 is a functionally relevant miR-383 target in PCa, we performed siRNA-mediated knockdown of CD44 in DU145/ PC3 cells followed by functional assays (Figures 5f-j) . We employed two sets of siRNA, si1-2, against CD44 to achieve efficient knockdown as assessed by qRT-PCR (Figure 5f , left panels) and validated by immunoblot analysis (Figure 5f , right panels). CD44 knockdown led to decreased cell viability (Figure 5g ), clonogenicity (Figure 5h ), invasiveness and motility ( Figure 5i ) and increased apoptosis (Figure 5j ). Also, CD44 knockdown induced G0-G1 cell cycle arrest in Du145 cell line (Supplementary Figure S6) . Thus, the functional consequences of CD44 knockdown functionally mimicked the effects of miR-383 overexpression. We also performed rescue experiments wherein CD44 ORF clone lacking miR-383-binding site in its 3′-UTR region was overexpressed along with miR-383 overexpression in Du145/ PC3 cells. We observed that the effects of miR-383 overexpression on invasion and migration were reversed upon CD44 overexpression as compared with control cells (Figure 5k ) reinforcing CD44 as a functional miR-383 target. However, the effects of miR-383 on cellular proliferation were not significantly abrogated (data not shown).
miR-383 inhibits tumor-initiating capacity of CD44+ prostate cancer cells in vitro
To further corroborate miR-383 mediated regulation of TICs via CD44, we asked whether modulation of miR-383 expression in the CD44+ subpopulation of xenograft tumors alters their tumorinitiating capacity. To test this, we purified CD44+ cells from DU145 mouse xenograft tumors followed by miR-383 transfections and in vitro functional assays ( Figure 6 ). Overexpression of miR-383 in CD44+ xenograft cells (Figure 6a ) led to markedly inhibited cellular growth (Figure 6b ). The tumor-initiating capacity of CD44+ cells was significantly inhibited by miR-383 expression as assessed by clonogenicity ( Figure 6c ) and sphere-formation assays (Figure 6d ). To explore the molecular basis for these effects, we performed Western Blot analysis of miR-CON/miR-383 transfected CD44+ xenograft cells (Figure 6e ). Interestingly, ectopic miR-383 expression in CD44+ PCa TICs led to marked downregulation of CD44 suggesting that miR-383 has remarkable potential to modulate this cell surface marker in PCa TIC/ stem cells.
miR-383 expression suppresses primary prostate xenograft tumor growth in vivo
In view of the in vitro tumor-suppressive effects of miR-383, we sought to determine the in vivo effects of miR-383 ( Figure 7) . We examined the effects of ectopic expression of miR-383 on both primary prostate xenograft tumor growth (Figures 7b and c) and metastases ( Figure 7d ). Bioluminescent PC-3M-luc-C6 cells were stably transfected with miR-CON/miR-383 ( Figure 7a ) and subcutaneously injected into nude mice to generate PCa xenograft tumors (Figure 7b ). Our results show that miR-383 overexpression led to significant inhibition of xenograft tumor growth confirming its tumor-suppressive effects in PCa. Further, in view of our present results suggesting that miR-383 is an important regulator of CD44, we asked whether this regulatory control functions in vivo. To test this, we extracted protein from xenograft tumors followed by western blotting for CD44 (Figure 6c ). Our data show that miR-383 expressing tumors (Figure 7c , lower panels) had lower CD44 protein levels as compared with control tumors (Figure 7c , upper panels). This further validates that CD44 is a direct miR-383 target in PCa.
miR-383 expression suppresses prostate cancer metastasis in vivo
Since CD44 has critical roles in tumor metastasis 10 and in view of our data implicating an important role of miR-383 in PCa invasiveness and migration due to CD44 regulation, we examined the effects of miR-383 overexpression on PCa metastasis. As an experimental metastasis model (Figure 7d) , bioluminescent PC-3M-luc-C6 cells stably expressing control miR/miR-383 were injected into the left ventricles of nude mice followed by periodic monitoring of the in vivo tumor burden by bioluminescent imaging (BLI). Interestingly, miR-383 had a strong inhibitory effect on metastases indicating its important 'anti-metastatic' role in PCa. To corroborate this, we examined whether low miR-383 expression is associated with metastasis in PCa clinical specimens (Figure 7e) . The TCGA cohort of prostate adenocarcinoma had 13 cases with lymph node metastasis (N1). 13/13 (100%) of these clinical tissues showed low miR-383 expression suggesting a significant inverse correlation between miR-383 expression and lymph node metastasis (P = 0.0451). However, this correlation could not be tested with the SFVAMC cohort as it had no metastatic cases.
DISCUSSION
A major PCa genomic alteration is frequent loss of chromosome 8p [11] [12] [13] [14] [15] [16] [17] with a common region of LOH at chr8p22 locus. 18 , 19 Here we demonstrate for the first time that a miRNA component of this region is frequently downregulated in PCa and has a critical role in determining the tumor-initiating potential and is involved in PCa metastasis via its direct regulation of CD44. Thus, our study is novel in that it associates a long observed genomic alteration to PCa stemness and metastasis via loss of a miRNA gene. To our knowledge, this is the first study that ascribes this role to this frequently lost genomic region in prostate cancer.
Importantly, our study reports for the first time that miR-383 is dysregulated in prostate carcinomas. Although miR-383 has been reported to be downregulated in other malignancies such as gliomas, medulloblastomas and pancreatic cancer, [27] [28] [29] [30] [31] [32] its role has never been explored in PCa. Till date, studies focused on microRNA expression profiling in PCa 36, 37 did not report significant alterations of this miRNA. However, our focused analyses of laser capture microdissected PCa clinical tissues compared with matched adjacent normals and reanalysis of TCGA data 36 revealed the widespread downregulation of this miRNA. Further, our analyses suggest that low miR-383 expression is associated with poor prognosis in PCa as clinical specimens with low miR-383 expression had poor survival outcome. Although our clinical samples do not suggest a statistically significant association between Gleason grade or tumor stage, miR-383 expression was significantly inversely correlated with lymph node metastasis. Also, our clinical cohort had a limited number of cases of pathological stage pT4 and metastatic samples. Hence, additional studies with larger datasets are warranted to confirm the prognostic potential of miR-383 in PCa. Previous studies suggest increased chr8p deletions with advanced tumor grade 38 and poor prognosis in PCa. 22 In particular, ch8p22 deletion has been shown to be a strong indicator for predicting disease progression 39 and PCa survival. Firefly luciferase values were normalized to Renilla luciferase activity and plotted as relative luciferase activity (*Po.05 as compared with miR-CON). (e) Relative miR-383 levels in purified CD44 − and CD44+ subpopulations of PCa xenografts (DU145, PC3 and LAPC9). Data were normalized to RNU48 control. (f) DU145/PC3 cells were transfected with two sets of siRNAs specific to CD44 (si1 and si2) or a nonspecific (NS) control siRNA/mock transfected for 72 h followed by functional assays. Left panels: relative CD44 mRNA expression after siRNA transfections as assessed by qRT-PCR. P-values are relative to NS siRNA. GAPDH was used as a control. Right panels: immunoblot analyses for CD44 protein expression after NS/CD44 siRNA transfections. GAPDH was used as a loading control. These findings are in agreement with earlier genomic studies suggesting that LOH at chr8p22 locus is an important event in the initiation of clinically significant PCa and is associated with subsequent progression to metastatic PCa. 21 Importantly, we demonstrate for the first time that miR-383 is a key negative regulator of PCa TICs via its direct regulation of CD44. Remarkably, ectopic expesssion of miR-383 in CD44+ PCa TICs led to marked downregulation of CD44 suggesting that miR-383 may regulate this subpopulation of PCa TICs/stem cells. Further, miR-383 overexpression in PCa cell lines led to direct repression of CD44 in vitro and in vivo, validating it as a direct miR-383 target.
Collectively, these data demonstrate that miR-383 is an important regulator of PCa TICs via direct regulation of CD44. CD44 has been previously reported to be regulated by miR-34a, 41 miR-708, 42 miR-373 and miR-520c 43 in PCa. Notably, Liu et al. demonstrated miR-34a as a key negative regulator of CD44+ PCa cells and miR-34a loss led to PCa development and metastasis. 41 Similarly, we demonstrated miR-708 as another key regulator of CD44+ subpopulation of PCa cells via its direct regulation of CD44. 42 Yang et al. 43 demonstrated that miR-373 and miR-520c suppress CD44 translation. Thus, CD44 may be combinatorially regulated by several miRNAs lending support to the concept that the miRNAs might cooperate to regulate specific genes by binding to the 3′-UTR of a single gene. 44, 45 As CD44 has been reported to have critical roles in tumor initiation and metastasis, 10 we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and PCa metastasis via its regulation of CD44. Although miR-383 was widely downregulated in PCa clinical specimens, 15% of prostate tumors showed upregulated miR-383 levels as compared with matched adjacent normal. In agreement with our hypothesis, these PCa cases were associated with better overall survival outcome.
Our study suggests that miR-383 inhibits PCa proliferation, migration and invasiveness and induces apoptosis. miR-383 expression has been previously reported to inhibit cell proliferation, migration, invasion and induce apoptosis in gliomas and medulloblastomas via targeting of cyclin D1, GADD45G (growth arrest and DNA-damage-inducible 45 gamma), peroxiredoxin 3 and insulin like growth factor receptor 1. [27] [28] [29] [30] [31] In pancreatic cancer, miR-383 suppresses growth and metastasis by direct targeting of ROBO3. 32 In skin cells, miR-383 is regulated by STAT3 that suppresses ATR controlling apoptosis. 46 Our study suggests that the effects of miR-383 on PCa cell lines are primarily mediated through its regulation of CD44. Considering the involvement of CD44, a transmembrane receptor for hyaluronan, in cell-cell and cell-matrix adhesion, migration, signaling and tumor metastasis, 10 we suggest that miR-383-CD44 regulatory interplay has an important role in prostate tumorigenesis. Reversal of the effects of miR-383 overexpression on invasion and migration upon CD44 overexpression lends support to our hypothesis. However, as the effects of miR-383 overexpression on cellular proliferation could not be 'rescued' by CD44, miR-383 may target additional genes. Future studies in the lab are directed towards identifying additional miR-383 targets in PCa.
Overall, we describe a novel finding that associates the frequently deleted chr8p22 locus to PCa stemness and metastasis via loss of a microRNA gene. Another miRNA component of this region, miR-320, has been similarly reported to be downregulated in PCa and suppress the cancer stem-cell-like characteristics of PCa cells by downregulating the Wnt/beta catenin signaling pathway. 47 miR-320 knockdown significantly increased cancer stem-like properties, and conversely, increased miR-320 miR-383 regulates CD44 N Bucay et al expression in prostate stem-like TICs significantly suppresses stem-cell-like properties of PCa cells. This study lends further support to our hypothesis linking chr8p22 locus with PCa stem cells. Also, miR-320 has been reported to be transactivated by miR-383 in granulosa cells (GC) leading to enhanced miR-320 mediated suppression of GC proliferation via its targeting of E2F1 and SF1. 48 Although we did not explore if such a regulatory interaction between miR-383 and miR-320 exists in PCa in the present study, future directions will be focused on this aspect.
Although histologic assessment has been used widely to assess PCa from tissue specimens, it has its own limitations as with serum PSA testing. 49, 50 Hence, microRNAs are being explored as alternative PCa biomarkers. 51 Our analyses suggest miR-383 as a potential PCa tissue diagnostic biomarker. Interestingly, serum PSA levels were inversely correlated with miR-383 expression in PCa tissues and factoring in tissue miR-383 expression with serum PSA increased the diagnostic potential of PSA in our clinical cohort. These data suggest that miR-383 expression can be a significant diagnostic parameter that can be used as a supplement to serum PSA testing. In view of our present results, ongoing studies in the lab are focused on testing miR-383 levels in serum from PCa patients and assessing its potential as an alternative biomarker with serum PSA.
Considering the association of chr8p22 loss with poor PCa prognosis, 22 our findings are highly significant. Our in vivo data showing a tumor-suppressive role of miR-383 in primary and metastatic PCa mouse models suggest that restoration of miR-383 expression may represent a therapeutic modality in PCa. 
MATERIALS AND METHODS

Cell lines and cell culture
Primary prostate epithelial cells and PCa cell lines (LNCaP, Du145, PC3) were obtained from the American Type Culture Collection (ATCC) and cultured under recommended conditions as described previously. 52 These cell lines were authenticated by DNA short-tandem repeat analysis by ATCC. The experiments with cell lines were performed within 6 months of their procurement/resuscitation.
Tissue samples
Formalin-fixed, paraffin-embedded (FFPE) PCa samples (n = 112) were obtained from the SFVAMC. Written informed consent was obtained from all patients and the study was approved by the UCSF Committee on Human Research. All tissue slides were reviewed by a board certified pathologist for the identification of cancer foci as well as adjacent normal glandular epithelium.
Animal studies
All animal care was in accordance with the guidelines of the SFVAMC and the study was approved by the San Francisco VA IACUC. Bioluminescent PC-3M-luc-C6 cells were stably transfected with miR-CON/miR-383 and either subcutaneously injected or were injected into the left ventricles of 6-week-old male nude mice (strain nu/nu; Simonsen Laboratories, n = 8 per group) as detailed in supplemental methods. 
